Cerebrolysin

Cerebrolysin is a porcine brain-derived peptide mixture used for neuroprotection and cognitive support. People typically run it at 500 mcg/day, though dosing schedules are often unspecified. The off-label evidence base is thinner than commonly suggested, with most exploratory indications lacking posted results, and community discussion notes variable individual response and recurring injection-site reactions.

Cerebrolysin

Research Evidence

Evidence shape

Clinical evidence for Cerebrolysin sits at a moderate tier, with the strongest data coming from Phase 3 trials that showed modest improvements in Alzheimer disease (≈‑0.6 points) and acute cerebral stroke treated within 12 hours (≈+1.0 units). The research portfolio covers 28 distinct neurological indications, backed by 12 sponsors and three blinded studies that have posted results, while the remaining trials are largely exploratory, single‑trial or still recruiting. The lack of published outcomes for most indications signals that robust evidence is limited to the few reported endpoints.

Depthhow much
39 registered trials
18 completed · 3 with posted results · 9 recruiting / active · combined n=543
Breadthhow many areas
28 indications mapped
3 with results · 23 thin / exploratory · 1 animal-only · 18 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
3 blinded with results · 12 distinct sponsors · AE rows aggregated from 3 trials · 9 linked publications on registered trials
Breadth and depth49 rows captured
Human
direct clinical signal
39
Animal
translational support
8
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
unknown
300 mg
$55.00
$0.18/mg
2
--
60 mg
$70.00
$1.17/mg
3
--
60 mg
$349.47
$5.82/mg

price offers can be sorted by column

Dosing & Protocol

How Cerebrolysin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 5
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

5 completed trials identified; trial dosing not reliably extracted from registry data.

Clinician practice
Doctor & published-protocol guidance
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 1
Typical dose
500 µg
250 µg
500 µg
1 mg
By reported cadence
Schedule unstated500 µg · n=1
Frequency
unspecified
Timing
unspecified
Route
IM/IV
Cycle
unspecified

Reported doses span 500 µg, most commonly 500 µg; most posters do not state a schedule.

1 source

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

Forum thread

Live community discussion for Cerebrolysin, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.